CN109423485B - Sucrose phosphorylase mutant and application thereof - Google Patents

Sucrose phosphorylase mutant and application thereof Download PDF

Info

Publication number
CN109423485B
CN109423485B CN201710740257.4A CN201710740257A CN109423485B CN 109423485 B CN109423485 B CN 109423485B CN 201710740257 A CN201710740257 A CN 201710740257A CN 109423485 B CN109423485 B CN 109423485B
Authority
CN
China
Prior art keywords
glycerol
basp
protein
sucrose
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201710740257.4A
Other languages
Chinese (zh)
Other versions
CN109423485A (en
Inventor
胡美荣
王雷
陈紫薇
彭颖
陶勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology of CAS
Original Assignee
Institute of Microbiology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Microbiology of CAS filed Critical Institute of Microbiology of CAS
Priority to CN201710740257.4A priority Critical patent/CN109423485B/en
Publication of CN109423485A publication Critical patent/CN109423485A/en
Application granted granted Critical
Publication of CN109423485B publication Critical patent/CN109423485B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01007—Sucrose phosphorylase (2.4.1.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention discloses a sucrose phosphorylase mutant and application thereof. The protein provided by the invention is obtained by replacing the 341 th amino acid residue of sucrose phosphorylase with other amino acid residue from leucine. The protein provided by the invention can be BaSP/L341D protein obtained by replacing the 341 th amino acid residue of sucrose phosphorylase with leucine into aspartic acid, and also can be BaSP/L341R protein obtained by replacing the 341 th amino acid residue of sucrose phosphorylase with leucine into arginine. The specificity of producing 2-glycerol glucoside by taking sucrose and glycerol as raw materials is remarkably improved and the yield of the byproduct 1-glycerol glucoside is reduced by point mutation of the 341 th amino acid residue primer of wild sucrose phosphorylase from bifidobacterium adolescentis. Has great application value in the field of 2-glycerol glucoside production.

Description

Sucrose phosphorylase mutant and application thereof
Technical Field
The invention belongs to the field of genetic engineering, and particularly relates to a sucrose phosphorylase mutant and application thereof.
Background
Sucrose phosphorylase (EC 2.4.1.7) belongs to family 13 glycosyltransferases (GH13) which catalyze the reversible phosphorylation of sucrose molecules in vivo (phosphate group as the glucose acceptor, products α -D-glucose-1 phosphate and D-fructose). Because of the stepwise reaction mechanism of the enzyme and the special structure of the active site, the glucosyl group acceptor in the reaction can be other molecules with biological activity such as ascorbic acid, hydroquinone, hesperidin, glycerol and the like besides the phosphoryl group. Glycosylation of these bioactive molecules can improve their stability, increase their solubility, enhance or even confer new physiological activities. The corresponding glycosylation product can be used as a functional additive of food or cosmetics, thereby having great application value and market prospect.
The alpha-glucosyl glycerol is also called 2-glycerol glucoside, and the structural formula is shown as a formula (I). The structural formula of the 1-glycerol glucoside is shown as a formula (II). The 2-glyceroglucoside can up-regulate the expression of aquaporin (aquaporin), has the physiological effect of moistening skin, can be used as a functional additive of cosmetics, and has larger market demand. The moisturizing effect of the 2-glycerol glucoside is better than that of the 1-glycerol glucoside. The 2-glycerol glucoside can be produced by taking sucrose and glycerol as raw materials under the action of sucrose phosphorylase. However, the prior art has a problem that 2-glyceroglucoside is produced and a large amount of 1-glyceroglucoside is produced as a by-product.
Figure BDA0001388959140000011
Disclosure of Invention
The invention aims to provide a sucrose phosphorylase mutant and application thereof.
The protein provided by the invention is obtained by replacing the 341 th amino acid residue of sucrose phosphorylase with other amino acid residue from leucine (L).
The protein provided by the invention can be BaSP/L341D protein. The BaSP/L341D protein is a mutant protein obtained by replacing the 341 th amino acid residue of sucrose phosphorylase from leucine (L) to aspartic acid (D).
The protein provided by the invention can be BaSP/L341R protein. The BaSP/L341R protein is a mutant protein obtained by replacing the 341 th amino acid residue of sucrose phosphorylase with leucine (L) to arginine (R).
The sucrose phosphorylase may be specifically (a1) or (a2) or (a3) as follows:
(a1) a protein consisting of an amino acid sequence shown in a sequence 1 in a sequence table;
(a2) a protein which is obtained by substituting and/or deleting and/or adding one or more amino acid residues of the amino acid sequence shown in the sequence 1, has the function of sucrose phosphorylase and is derived from the sequence 1;
(a3) a protein derived from bifidobacterium adolescentis and having more than 90% identity with the protein shown in the sequence 1.
The gene coding the BaSP/L341D protein also belongs to the protection scope of the invention. The gene encoding the BaSP/L341D protein may specifically be (b1) or (b2) or (b5) or (b6) as follows.
The gene coding the BaSP/L341R protein also belongs to the protection scope of the invention. The gene encoding the BaSP/L341R protein may specifically be (b3) or (b4) or (b5) or (b6) as follows.
(b1) The coding region is a DNA molecule which mutates the 1021-1023 bit nucleotide of the double-stranded DNA molecule shown in the sequence 2 of the sequence table from "ctc" to "GAC".
(b2) The double-stranded DNA molecule shown in the sequence 2 of the sequence table has the mutation of the 1021-1023 bit nucleotide from "ctc" to "GAC".
(b3) The coding region is a DNA molecule which mutates the 1021-1023 bit nucleotide of the double-stranded DNA molecule shown in the sequence 2 of the sequence table from 'ctc' to 'CGC'.
(b4) The double-stranded DNA molecule shown in the sequence 2 of the sequence table has the mutation of the 1021-1023 bit nucleotide from "ctc" to "CGC".
(b5) A DNA molecule which hybridizes with the DNA sequence defined in (b1) or (b2) or (b3) or (b4) under stringent conditions and encodes the protein.
(b6) A DNA molecule which has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% or more homology with the DNA sequence defined in (b1) or (b2) or (b3) or (b4) and encodes the protein.
The stringent conditions can be hybridization and washing with 0.1 XSSPE (or 0.1 XSSC), 0.1% SDS solution at 65 ℃ in DNA or RNA hybridization experiments.
Expression cassettes, recombinant vectors, recombinant bacteria or transgenic cell lines containing the gene encoding the BaSP/L341D protein belong to the scope of protection of the present invention. The recombinant bacterium containing the gene encoding the BaSP/L341D protein was designated as recombinant bacterium BaSP/L341D. The recombinant bacterium, BaSP/L341D, may be specifically a recombinant bacterium obtained by introducing a recombinant plasmid pBAD-BaSP/L341D into Escherichia coli BW 25113. The recombinant plasmid pBAD-BaSP/L341D is a recombinant plasmid obtained by inserting a gene encoding a BaSP/L341D protein into the multiple cloning site (for example, between XhoI and PstI cleavage sites) of the vector pBAD/HisB.
Expression cassettes, recombinant vectors, recombinant bacteria or transgenic cell lines containing the gene encoding the BaSP/L341R protein belong to the scope of protection of the present invention. The recombinant bacterium containing the gene encoding the BaSP/L341R protein was designated as recombinant bacterium BaSP/L341R. The recombinant bacterium, BaSP/L341R, may be specifically a recombinant bacterium obtained by introducing a recombinant plasmid pBAD-BaSP/L341R into Escherichia coli BW 25113. The recombinant plasmid pBAD-BaSP/L341R is a recombinant plasmid obtained by inserting a gene encoding a BaSP/L341R protein into the multiple cloning site (for example, between XhoI and PstI cleavage sites) of the vector pBAD/HisB.
The invention also protects the application of the BaSP/L341D protein in the production of 2-glycerol glucoside.
The invention also protects the application of the recombinant bacterium BaSP/L341D in the production of 2-glycerol glucoside.
The invention also protects the application of the BaSP/L341D protein in the production of 2-glycerol glucoside by using sucrose and glycerol as raw materials.
The invention also protects the application of the recombinant bacterium BaSP/L341D in the production of 2-glycerol glucoside by taking sucrose and glycerol as raw materials.
The invention also protects the application of the BaSP/L341R protein in the production of 2-glycerol glucoside.
The invention also protects the application of the recombinant bacterium BaSP/L341R in the production of 2-glycerol glucoside.
The invention also protects the application of the BaSP/L341R protein in the production of 2-glycerol glucoside by using sucrose and glycerol as raw materials.
The invention also protects the application of the recombinant bacterium BaSP/L341R in the production of 2-glycerol glucoside by taking sucrose and glycerol as raw materials.
The invention also provides a method for producing 2-glycerol glucoside, which comprises the following steps: sucrose and glycerol are used as raw materials, and under the action of BaSP/L341D protein, 2-glycerol glucoside is obtained.
The invention also provides a method for producing 2-glycerol glucoside, which comprises the following steps: taking sucrose and glycerol as raw materials, and obtaining the 2-glycerol glucoside under the action of a recombinant bacterium BaSP/L341D.
The method comprises the following steps: culturing a recombinant bacterium BaSP/L341D, performing L-arabinose induction in the culture process, and then centrifuging to collect the bacterium; and adding the thalli, glycerol and sucrose into a buffer system, and reacting to obtain the 2-glycerol glucoside. The mass ratio of the thalli, the glycerol and the sucrose is as follows: 10: 200: 200. in the reaction system, the initial concentrations of the components were as follows: 10g/L of thallus, 200g/L of glycerol and 200g/L of sucrose. The mass of the cells is wet weight. The buffer system is phosphate buffer solution with pH 6.0. The reaction conditions are specifically as follows: shaking at 30 deg.C and 80rpm for 60 h.
The method specifically comprises the following steps: culturing recombinant bacteria BaSP/L341D to OD in liquid LB culture medium600nm0.6-0.8 (specifically 0.7), adding L-arabinose to the culture system to make the concentration of the L-arabinose be 0.2g/100mL, culturing at 30 ℃ for 12 hours under the condition of 200rpm oscillation, and centrifuging to collect the thallus; and adding the thalli, glycerol and sucrose into a buffer system, and reacting to obtain the 2-glycerol glucoside. The mass ratio of the thalli, the glycerol and the sucrose is as follows: 10: 200: 200. in the reaction system, the initial concentrations of the components were as follows: 10g/L of thallus, 200g/L of glycerol and 200g/L of sucrose. The mass of the cells is wet weight. The buffer system is phosphate buffer solution with pH 6.0. The reaction conditions are specifically as follows: shaking at 30 deg.C and 80rpm for 60 h.
The invention also provides a method for producing 2-glycerol glucoside, which comprises the following steps: sucrose and glycerol are used as raw materials, and under the action of BaSP/L341R protein, 2-glycerol glucoside is obtained.
The invention also provides a method for producing 2-glycerol glucoside, which comprises the following steps: taking sucrose and glycerol as raw materials, and obtaining the 2-glycerol glucoside under the action of a recombinant bacterium BaSP/L341R.
The method comprises the following steps: culturing a recombinant bacterium BaSP/L341R, performing L-arabinose induction in the culture process, and then centrifuging to collect the bacterium; and adding the thalli, glycerol and sucrose into a buffer system, and reacting to obtain the 2-glycerol glucoside. The mass ratio of the thalli, the glycerol and the sucrose is as follows: 10: 200: 200. in the reaction system, the initial concentrations of the components were as follows: 10g/L of thallus, 200g/L of glycerol and 200g/L of sucrose. The mass of the cells is wet weight. The buffer system is phosphate buffer solution with pH 6.0. The reaction conditions are specifically as follows: shaking at 30 deg.C and 80rpm for 60 h.
The method specifically comprises the following steps: culturing recombinant bacteria BaSP/L341R to OD in liquid LB culture medium600nm0.6-0.8 (specifically 0.7), adding L-arabinose to the culture system to make the concentration of the L-arabinose be 0.2g/100mL, culturing at 30 ℃ for 12 hours under the condition of 200rpm oscillation, and centrifuging to collect the thallus; and adding the thalli, glycerol and sucrose into a buffer system, and reacting to obtain the 2-glycerol glucoside. The mass ratio of the thalli, the glycerol and the sucrose is as follows: 10: 200: 200. in the reaction system, the initial concentrations of the components were as follows: 10g/L of thallus, 200g/L of glycerol and 200g/L of sucrose. The mass of the cells is wet weight. The buffer system is phosphate buffer solution with pH 6.0. The reaction conditions are specifically as follows: shaking at 30 deg.C and 80rpm for 60 h.
The invention obviously improves the specificity of producing 2-glycerol glucoside by taking sucrose and glycerol as raw materials and reduces the yield of a byproduct 1-glycerol glucoside by introducing point mutation into the 341 th amino acid residue of wild sucrose phosphorylase from bifidobacterium adolescentis. The invention has great application value in the field of production of 2-glycerol glucoside.
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged. Unless otherwise specified, all phosphate buffers in the examples were 50mM PBS buffer. For chromatograms of different reactions under the same condition parameters, the retention time of a target peak has a certain error range, and generally, the difference can be regarded as an error within 0.1 min. 2-glycerol glucoside standard: carbofuran, cat # J60-H943140. In the examples, the cell weights were wet weights.
Bifidobacterium adolescentis (Bifidobacterium adolescentis): CGMCC 1.2190. Vector pBAD/HisB: invitrogen, catalog number V430-01. Coli BW 25113: biovector NTCC INC, cat # 355297.
Example 1 construction of recombinant bacterium
Construction of recombinant bacterium BaSP
1. Extracting the genome DNA of the bifidobacterium adolescentis.
2. And (3) performing PCR amplification by using the genomic DNA obtained in the step (1) as a template and adopting a primer pair consisting of F1 and R1, and recovering a PCR amplification product.
F1：5’-GCCTGGTGCCGCGCGGCAGCCTCGAGatgaaaaacaaggtgcag-3’；
R1：5’-CAGCTGCAGACCGAGCTCACCCTGCAGtcaggcgacgacaggcggattg-3’。
3. And (3) taking the PCR amplification product obtained in the step (2), carrying out double enzyme digestion by using restriction enzymes XhoI and PstI, and recovering the enzyme digestion product.
4. The vector pBAD/HisB was digested with restriction enzymes XhoI and PstI, and the vector backbone of about 4000bp was recovered.
5. And (4) connecting the enzyme digestion product in the step (3) with the vector framework in the step (4) to obtain the recombinant plasmid pBAD-BaSP.
According to the sequencing result, the structure of the recombinant plasmid pBAD-BaSP is described as follows: the small fragment between the XhoI and PstI cleavage sites of the vector pBAD/HisB was substituted for the double-stranded DNA molecule shown in sequence 2 of the sequence listing. The DNA molecule shown in the sequence 2 of the sequence table encodes BaSP protein shown in the sequence 1 of the sequence table.
6. The recombinant plasmid pBAD-BaSP is introduced into escherichia coli BW25113 to obtain a recombinant bacterium BaSP.
Secondly, constructing a recombinant bacterium BaSP/L341D
1. The recombinant plasmid pBAD-BaSP is used as a template, and a primer pair consisting of F2 and R2 is adopted to introduce single-point mutation, so that the recombinant plasmid pBAD-BaSP/L341D is obtained.
F2：5’-TCCAATGACGACCTCTACCAGGTCAACAG-3’；
R2：5’-GAGGTCGTCATTGGATGCGGCGGCGCCAG-3’。
According to the sequencing results, the recombinant plasmid pBAD-BaSP/L341D was structurally described as follows: the double-stranded DNA molecule 1021-1023 nucleotide shown in the sequence 2 of the sequence table in the recombinant plasmid pBAD-BaSP is mutated from "ctc" to "GAC". The mutated DNA molecule encodes the BaSP/L341D protein. The difference between the BaSP/L341D protein and the BaSP protein is only that the 341 th amino acid residue of the BaSP protein is mutated from leucine (L) to aspartic acid (D).
2. The recombinant plasmid pBAD-BaSP/L341D was introduced into Escherichia coli BW25113 to obtain recombinant strain BaSP/L341D.
Thirdly, constructing a recombinant bacterium BaSP/L341R
1. The recombinant plasmid pBAD-BaSP is used as a template, and a primer pair consisting of F3 and R3 is adopted to introduce single-point mutation, so that the recombinant plasmid pBAD-BaSP/L341R is obtained.
F3：5’-TCCAATCGCGACCTCTACCAGGTCAACAG-3’；
R3：5’-GAGGTCGCGATTGGATGCGGCGGCGCCAG-3’。
According to the sequencing results, the recombinant plasmid pBAD-BaSP/L341R was structurally described as follows: the double-stranded DNA molecule 1021-1023 nucleotide shown in the sequence 2 of the sequence table in the recombinant plasmid pBAD-BaSP is mutated from "ctc" to "CGC". The mutated DNA molecule encodes the BaSP/L341R protein. The difference between the BaSP/L341R protein and the BaSP protein is only that the 341 th amino acid residue of the BaSP protein is mutated from leucine (L) to arginine (R).
2. The recombinant plasmid pBAD-BaSP/L341R was introduced into Escherichia coli BW25113 to obtain recombinant strain BaSP/L341R.
Fourthly, constructing recombinant bacteria pBAD
The vector pBAD/HisB was introduced into E.coli BW25113 to obtain recombinant strain pBAD.
Example 2 preparation of 2-Glycerol glucoside Using recombinant bacteria
Respectively carrying out the following steps on the recombinant bacterium BaSP, the recombinant bacterium BaSP/L341D, the recombinant bacterium BaSP/L341R or the recombinant bacterium pBAD:
1. taking a monoclonal of the recombinant bacteria, inoculating the monoclonal to a liquid LB culture medium, and carrying out shaking culture at 37 ℃ and 220rpm until the recombinant bacteria reach OD600nm0.7 (OD in practical use)600nm0.6-0.8).
2. After completion of step 1, L-arabinose was added to the culture system so that the concentration thereof in the culture system became 0.2g/100mL, and the culture was carried out at 30 ℃ for 12 hours with shaking at 200 rpm.
3. After the step 2 is completed, the whole culture system is taken, centrifuged at 6000rpm for 15min at 4 ℃, and thalli precipitates are collected.
4. Preparing a reaction system.
The reaction system consists of the thallus precipitate obtained in the step 3, glycerol, sucrose and phosphate buffer solution with pH of 6.0. In the reaction system, the initial concentrations of the components were as follows: 10g/L of thallus, 200g/L of glycerol and 200g/L of sucrose.
Reaction conditions are as follows: shaking at 30 deg.C and 80rpm for 60 h.
5. After the step 4 is completed, taking the reaction system, and detecting the content of the 2-glycerol glucoside in the reaction system, wherein the specific steps are as follows:
(1) the reaction system was centrifuged at 12000rpm for 2min, and the supernatant was collected.
(2) Diluting the supernatant obtained in the step (1) with distilled water to obtain a supernatant.
(3) And (3) taking the sample liquid obtained in the step (2), and detecting the content of the 2-glycerol glucoside by adopting a high performance liquid chromatography. HPLC system: agilent 1260; a chromatographic column: waters Amide columns (34.6X 150mm,3.5 μm); the mobile phase consists of 800 parts by volume of acetonitrile and 200 parts by volume of 1 per mill of ammonia water;
the sample volume is 10 mu L; the column temperature is 30 ℃; the flow rate is 1 mL/min; and detecting by an RID detector.
Under the chromatographic conditions, the peak position of the 2-glycerol glucoside standard substance is 8.141min, and the peak position of the 1-glycerol glucoside standard substance is 9.108 min.
The standard curve equation of the content of the 2-glycerol glucoside and the peak area is established by using the 2-glycerol glucoside standard substance as follows: 29060x (R)20.9999); wherein x is the peak area in the HPLC chromatogram, and y is the concentration of 2-glycerol glucoside, and the unit is g/L.
The standard curve equation of the content of the 1-glycerol glucoside and the peak area is established by using the 1-glycerol glucoside standard substance as follows: Y29060X (R)20.9999); wherein X is the peak area in an HPLC chromatogram, and Y is the concentration of 1-glycerol glucoside, and the unit is g/L.
In the reaction system of the step 4 for completing the recombinant bacterium BaSP, the concentration of 2-glycerol glucoside is 45g/L (average value of 10 repeated tests), the concentration of 1-glycerol glucoside is 30g/L (average value of 10 repeated tests), and the yield ratio of 2-glycerol glucoside to 1-glycerol glucoside is 1.5: 1.
In the reaction system of the recombinant bacterium BaSP/L341D in the step 4, the concentration of 2-glyceroglucoside is 60g/L (average value of 10 repeated tests), the concentration of 1-glyceroglucoside is 21g/L (average value of 10 repeated tests), and the yield ratio of 2-glyceroglucoside to 1-glyceroglucoside is 2.86: 1.
In the reaction system of the recombinant bacterium BaSP/L341R in the step 4, the concentration of 2-glyceroglucoside is 55g/L (average value of 10 repeated tests), the concentration of 1-glyceroglucoside is 17g/L (average value of 10 repeated tests), and the yield ratio of 2-glyceroglucoside to 1-glyceroglucoside is 3.24: 1.
The recombinant pBAD has a concentration of 2-glycerol glucoside (average value of 10 repeated tests) and a concentration of 1-glycerol glucoside (average value of 10 repeated tests) in the reaction system for completing the step 4.
Sequence listing
<110> institute of microbiology of Chinese academy of sciences
<120> sucrose phosphorylase mutant and application thereof
<130> GNCYX171491
<141> 2017-08-25
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 504
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Met Lys Asn Lys Val Gln Leu Ile Thr Tyr Ala Asp Arg Leu Gly Asp
1 5 10 15
Gly Thr Ile Lys Ser Met Thr Asp Ile Leu Arg Thr Arg Phe Asp Gly
20 25 30
Val Tyr Asp Gly Val His Ile Leu Pro Phe Phe Thr Pro Phe Asp Gly
35 40 45
Ala Asp Ala Gly Phe Asp Pro Ile Asp His Thr Lys Val Asp Glu Arg
50 55 60
Leu Gly Ser Trp Asp Asp Val Ala Glu Leu Ser Lys Thr His Asn Ile
65 70 75 80
Met Val Asp Ala Ile Val Asn His Met Ser Trp Glu Ser Lys Gln Phe
85 90 95
Gln Asp Val Leu Ala Lys Gly Glu Glu Ser Glu Tyr Tyr Pro Met Phe
100 105 110
Leu Thr Met Ser Ser Val Phe Pro Asn Gly Ala Thr Glu Glu Asp Leu
115 120 125
Ala Gly Ile Tyr Arg Pro Arg Pro Gly Leu Pro Phe Thr His Tyr Lys
130 135 140
Phe Ala Gly Lys Thr Arg Leu Val Trp Val Ser Phe Thr Pro Gln Gln
145 150 155 160
Val Asp Ile Asp Thr Asp Ser Asp Lys Gly Trp Glu Tyr Leu Met Ser
165 170 175
Ile Phe Asp Gln Met Ala Ala Ser His Val Ser Tyr Ile Arg Leu Asp
180 185 190
Ala Val Gly Tyr Gly Ala Lys Glu Ala Gly Thr Ser Cys Phe Met Thr
195 200 205
Pro Lys Thr Phe Lys Leu Ile Ser Arg Leu Arg Glu Glu Gly Val Lys
210 215 220
Arg Gly Leu Glu Ile Leu Ile Glu Val His Ser Tyr Tyr Lys Lys Gln
225 230 235 240
Val Glu Ile Ala Ser Lys Val Asp Arg Val Tyr Asp Phe Ala Leu Pro
245 250 255
Pro Leu Leu Leu His Ala Leu Ser Thr Gly His Val Glu Pro Val Ala
260 265 270
His Trp Thr Asp Ile Arg Pro Asn Asn Ala Val Thr Val Leu Asp Thr
275 280 285
His Asp Gly Ile Gly Val Ile Asp Ile Gly Ser Asp Gln Leu Asp Arg
290 295 300
Ser Leu Lys Gly Leu Val Pro Asp Glu Asp Val Asp Asn Leu Val Asn
305 310 315 320
Thr Ile His Ala Asn Thr His Gly Glu Ser Glu Ala Ala Thr Gly Ala
325 330 335
Ala Ala Ser Asn Leu Asp Leu Tyr Gln Val Asn Ser Thr Tyr Tyr Ser
340 345 350
Ala Leu Gly Cys Asn Asp Gln His Tyr Ile Ala Ala Arg Ala Val Gln
355 360 365
Phe Phe Leu Pro Gly Val Pro Gln Val Tyr Tyr Val Gly Ala Leu Ala
370 375 380
Gly Lys Asn Asp Met Glu Leu Leu Asn Lys Thr Asn Asn Gly Arg Asp
385 390 395 400
Ile Asn Arg His Tyr Tyr Ser Thr Ala Glu Ile Asp Glu Asn Leu Lys
405 410 415
Arg Pro Val Val Lys Ala Leu Asn Ala Leu Ala Lys Phe Arg Asn Glu
420 425 430
Leu Asp Ala Phe Asp Gly Thr Phe Ser Tyr Thr Thr Pro Thr Asp Thr
435 440 445
Ser Ile Ser Phe Thr Trp Arg Gly Glu Thr Ser Glu Ala Thr Leu Thr
450 455 460
Phe Glu Pro Lys Arg Gly Leu Gly Val Asp Asn Thr Thr Pro Val Ala
465 470 475 480
Met Leu Glu Trp His Asp Ser Ala Gly Asp His Arg Ser Asp Asp Leu
485 490 495
Ile Ala Asn Pro Pro Val Val Ala
500
<210> 2
<211> 1515
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atgaaaaaca aggtgcagct catcacttac gccgaccgcc ttggcgacgg caccatcaag 60
tcgatgaccg acattctgcg cacccgcttc gacggcgtgt acgacggcgt tcacatcctg 120
ccgttcttca ccccgttcga cggcgccgac gcaggcttcg acccgatcga ccacaccaag 180
gtcgacgaac gtctcggcag ctgggacgac gtcgccgaac tctccaagac ccacaacatc 240
atggtcgacg ccatcgtcaa ccacatgagt tgggaatcca agcagttcca ggacgtgctg 300
gccaagggcg aggagtccga atactatccg atgttcctca ccatgagctc cgtgttcccg 360
aacggcgcca ccgaagagga cctggccggc atctaccgtc cgcgtccggg cctgccgttc 420
acccactaca agttcgccgg caagacccgc ctcgtgtggg tcagcttcac cccgcagcag 480
gtggacatcg acaccgattc cgacaagggt tgggaatacc tcatgtcgat tttcgaccag 540
atggccgcct ctcacgtcag ctacatccgc ctcgacgccg tcggctatgg cgccaaggaa 600
gccggcacca gctgcttcat gaccccgaag accttcaagc tgatctcccg tctgcgtgag 660
gaaggcgtca agcgcggtct ggaaatcctc atcgaagtgc actcctacta caagaagcag 720
gtcgaaatcg catccaaggt ggaccgcgtc tacgacttcg ccctgcctcc gctgctgctg 780
cacgcgctga gcaccggcca cgtcgagccc gtcgcccact ggaccgacat acgcccgaac 840
aacgccgtca ccgtgctcga tacgcacgac ggcatcggcg tgatcgacat cggctccgac 900
cagctcgacc gctcgctcaa gggtctcgtg ccggatgagg acgtggacaa cctcgtcaac 960
accatccacg ccaacaccca cggcgaatcc gaagcagcca ctggcgccgc cgcatccaat 1020
ctcgacctct accaggtcaa cagcacctac tattcggcgc tcgggtgcaa cgaccagcac 1080
tacatcgccg cccgcgcggt gcagttcttc ctgccgggcg tgccgcaagt ctactacgtc 1140
ggcgcgctcg ccggcaagaa cgacatggag ctgctgaaca agacgaataa cggccgcgac 1200
atcaatcgcc attactactc caccgcggaa atcgacgaga acctcaagcg tccggtcgtc 1260
aaggccctga acgcgctcgc caagttccgc aacgagctcg acgcgttcga cggcacgttc 1320
tcgtacacca ccccgaccga cacgtccatc agcttcacct ggcgcggcga aaccagcgaa 1380
gccacgctga cgttcgagcc gaagcgcggt ctcggtgtgg acaacactac gccggtcgcc 1440
atgttggaat ggcatgattc cgcgggagac caccgttcgg atgatctgat cgccaatccg 1500
cctgtcgtcg cctga 1515

Claims (8)

1. A protein, which is obtained by replacing the 341 th amino acid residue of sucrose phosphorylase with another amino acid residue from leucine; the other amino acid residue is aspartic acid or arginine; the sucrose phosphorylase is a protein consisting of an amino acid sequence shown in a sequence 1 in a sequence table.
2. A gene encoding the protein of claim 1.
3. The gene of claim 2, wherein: the gene is a DNA molecule of (b1) or (b2) as follows:
(b1) the coding region is a DNA molecule which mutates the 1021-1023 bit nucleotide of the double-stranded DNA molecule shown in the sequence 2 of the sequence table from 'ctc' to 'GAC';
(b2) the coding region is a DNA molecule which mutates the 1021-1023 bit nucleotide of the double-stranded DNA molecule shown in the sequence 2 of the sequence table from 'ctc' to 'CGC'.
4. An expression cassette, recombinant vector, recombinant bacterium or transgenic cell line comprising the gene of claim 2 or 3.
5. Use of the protein of claim 1 or the recombinant bacterium of claim 4 for producing 2-glyceroglucoside.
6. Use of the protein of claim 1 or the recombinant bacterium of claim 4 for producing 2-glyceroglucoside from sucrose and glycerol.
7. A method for producing 2-glyceroglucoside, comprising the steps of: 2-glycerol glucoside is obtained by using sucrose and glycerol as raw materials under the action of the protein of claim 1.
8. A method for producing 2-glyceroglucoside, comprising the steps of: taking sucrose and glycerol as raw materials, and obtaining the 2-glycerol glucoside under the action of the recombinant bacterium disclosed in claim 4.
CN201710740257.4A 2017-08-25 2017-08-25 Sucrose phosphorylase mutant and application thereof Expired - Fee Related CN109423485B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710740257.4A CN109423485B (en) 2017-08-25 2017-08-25 Sucrose phosphorylase mutant and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710740257.4A CN109423485B (en) 2017-08-25 2017-08-25 Sucrose phosphorylase mutant and application thereof

Publications (2)

Publication Number Publication Date
CN109423485A CN109423485A (en) 2019-03-05
CN109423485B true CN109423485B (en) 2021-12-24

Family

ID=65501110

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710740257.4A Expired - Fee Related CN109423485B (en) 2017-08-25 2017-08-25 Sucrose phosphorylase mutant and application thereof

Country Status (1)

Country Link
CN (1) CN109423485B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107858335B (en) * 2017-12-25 2021-07-16 南京华狮新材料有限公司 Sucrose phosphorylase mutant and application thereof in production of glycerol glucoside
CN110358750B (en) * 2019-08-06 2023-02-28 江苏诚信药业有限公司 Novel sucrose phosphorylase mutant and application thereof in synthesis of glycerol glucoside
CN110734899B (en) * 2019-10-31 2021-06-18 江南大学 Sucrose phosphorylase mutant with improved enzyme activity and construction method and application thereof
CN111172127A (en) * 2020-01-17 2020-05-19 浙江工业大学 Application of sucrose phosphorylase in preparation of glycerol glucoside
CN111621483B (en) * 2020-06-05 2021-11-23 江南大学 Sucrose phosphorylase mutant and application thereof
CN114015735B (en) * 2021-11-25 2023-11-14 江南大学 Method for synthesizing aspergillus niger disaccharide by cascading and catalyzing sucrose phosphorylase and glucose isomerase
CN114317477B (en) * 2021-12-30 2023-07-14 南京诺云生物科技有限公司 Sucrose phosphorylase and glucose-1-phosphoric acid production process
CN114317476B (en) * 2021-12-30 2023-07-14 南京诺云生物科技有限公司 Biocatalysis production process of glucosyl glycerine and sucrose phosphorylase thereof
CN114250207B (en) * 2021-12-31 2023-08-11 南京诺云生物科技有限公司 High-activity sucrose phosphorylase and application thereof
CN114703158B (en) * 2022-03-10 2024-04-05 浙江工业大学 Sucrose phosphorylase mutant, coding gene and application thereof
CN115141815B (en) * 2022-06-20 2023-10-27 华熙生物科技股份有限公司 Sucrose phosphorylase mutant and application thereof
CN115044568B (en) * 2022-06-20 2024-01-23 华熙生物科技股份有限公司 High-stability sucrose phosphorylase mutant and application thereof
CN118147105B (en) * 2024-05-09 2024-08-02 西宝生物科技（上海）股份有限公司 Efficient preparation method of sucrose phosphorylase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biocatalytic Synthesis of the Rare Sugar Kojibiose: Process Scale-Up and Application Testing;Koen Beerens等;《J. Agric. Food Chem.》;20170630;第65卷;6030-6041 *
sucrose phosphorylase [Bifidobacterium adolescentis];NCBI;《NCBI Reference Sequence: WP_011742626.1》;20130516;序列及注释 *
长双歧杆菌蔗糖磷酸化酶定点突变及其催化机理的研究;于丽;《中国优秀硕士学位论文全文数据库 基础科学辑》;20150115(第1期);A006-76 *

Also Published As

Publication number Publication date
CN109423485A (en) 2019-03-05

Similar Documents

Publication Publication Date Title
CN109423485B (en) Sucrose phosphorylase mutant and application thereof
CN107858335B (en) Sucrose phosphorylase mutant and application thereof in production of glycerol glucoside
CN109563499B (en) Novel thermostable fructose-6-phosphate-3-epimerase and method for producing allose using the same
CN111718915B (en) Nicotinamide phosphoribosyl transferase mutant, recombinant expression vector and recombinant bacterium containing mutant and application
CN107889504B (en) Method for preparing nicotinamide mononucleotide
CN109790524B (en) Novel thermotolerant phosphatase specific to tagatose-6-phosphate and method for producing tagatose using same
CN109750011B (en) Mannose-6-phosphate phosphatase and biological preparation method of mannose
KR20170141176A (en) Hexuronate c4-epimerase variants with improved conversion activity and method for production of d-tagatose using them
CN111344399B (en) UDP-glucosyltransferase mutant, application thereof and method for preparing rebaudioside D by using same
CN108728421B (en) Carbonyl reductase mutant and application thereof
JP2018536425A (en) Hexuronic acid C4-epimerase mutant with enhanced D-tagatose conversion activity and method for producing D-tagatose using the same
US20190322991A1 (en) Method for enzymatically preparing highly concentrated myo-inositol
CN110358750B (en) Novel sucrose phosphorylase mutant and application thereof in synthesis of glycerol glucoside
CN116240190A (en) Sucrose phosphorylase mutant, coding gene and application
CN112342178B (en) Recombinant microorganism, preparation method thereof and application thereof in producing tagatose
CN110904088B (en) High-temperature-resistant D-psicose3-epimerase, mutant and application thereof
KR102308173B1 (en) A Novel Fructose C4 epimerases and Preparation Method for producing Tagatose using the same
KR101708974B1 (en) Novel sucrose isomerase and process for preparing the same
CN109628476B (en) Method for producing 4-hydroxyisoleucine by using whole cell transformation
CN114409751B (en) YH 66-04470 gene mutant recombinant bacterium and application thereof in preparation of arginine
KR102063908B1 (en) A novel thermostable fructose-6-phosphate 3-epimerase and methods for producing allulose using the same
CN113637652B (en) Adenylyltransferase mutant and application thereof
KR101768748B1 (en) Mutated sucrose isomerase and process for preparing the same
CN111057697A (en) High-temperature-resistant TIM barrel protein mutant and application thereof
CN115044568B (en) High-stability sucrose phosphorylase mutant and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211224